Continuous Manufacturing: The Facts and the Future

4 Feb 2019

Gaining momentum in the pharmaceutical industry, continuous manufacturing (CM) presents a new approach to oral solid dosage (OSD) form production and meets the industry’s demands for faster product development, reduced costs, and increased manufacturing flexibility.

Environmentally friendly with a much smaller footprint, CM is helping the pharmaceutical industry to produce higher quality products, enhance drug safety and reduce its industrial footprint, which provides significant advantages.

Continuous Manufacturing: The Facts and the Future

To examine the fact and fiction of continuous manufacturing in the pharmaceutical industry, GEA, Siemens and Perceptive Engineering will jointly host an inaugural three-day conference comprising two days of presentations from early adopters, a visit to the National Formulation Centre in Sedgefield, UK, courtesy of the Centre for Process Innovation (CPI), and a chance to visit the MSD Cramlington plant (Continuous Direct Compression and Coating).

Taking place on 26–28 March 2019 in Durham, UK, with an expected attendance of 80–120 delegates, the event will focus on the real-life experiences of existing CM users in the development and manufacture of oral solid dosage forms.

Topics on the agenda will include the current status of “going conti” as well as future plans and expectations. Confirmed speakers currently include experts from AstraZeneca, Bayer, CMAC, GSK, Janssen, Merck, RCPE, UCB Pharma and University of Sheffield, to name a few.

Read More